LARGEST STATISTICALLY SIGNIFICANT STUDY BY 6,200 MULTI-COUNTRY PHYSICIANS ON COVID-19 UNCOVERS TREATMENT PATTERNS AND PUTS PANDEMIC IN CONTEXT

Sermo Reports on Hydroxychloroquine Efficacy, Rise in Prophylaxis Use; Over 80% Expect 2nd Outbreak

NEW YORK, April 3 (Bernama-BUSINESS WIRE) -- Widespread confusion, conflicting reports, inconsistent testing, and off-indication use of existing and experimental drugs has resulted in no single source of information from the frontlines. To create a centralized and dynamic knowledge base, Sermo, the largest global healthcare polling company and social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries. The study was completed in three days. Data covers current treatment and prophylaxis options, timing to the outbreak peak, ethical choices, effectiveness of government responses, and much more. Multiple study waves including a deeper dive into treatments will be conducted over the next several weeks. To view results and countries visit sermo.com.

Key findings; Sermo Real Time Barometer *:

Treatments & Efficacy

· The three most commonly prescribed treatments amongst COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine
· Hydroxychloroquine usage amongst COVID-19 treaters is 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in the U.S., 17% in Germany, 16% in Canada, 13% in the UK, and 7% in Japan
· Hydroxychloroquine was overall chosen as the most effective therapy amongst COVID-19 treaters from a list of 15 options. (37% of COVID-19 treaters)
o 75% in Spain, 53% Italy, 44% in China, 43% in Brazil, 29% in France, 23% in the U.S., and 13% in the UK

· The two most common treatment regimens for Hydroxychloroquine were:
o (38%) 400mg twice daily on day one; 400 mg daily for five days
o (26%) 400mg twice daily on day one; 200mg twice daily for four days
· Outside the U.S., Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the U.S. it was most commonly used for high risk diagnosed patients
· Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients
http://mrem.bernama.com/viewsm.php?idm=37096